Abbisko Cayman (8ZD) Stock Overview

Engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. More details

8ZD fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	1/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 63% below our estimate of its fair value

Revenue is forecast to grow 13.76% per year

Earnings grew by 95.2% over the past year

Analysts in good agreement that stock price will rise by 105.4%

Risk Analysis

Earnings are forecast to decline by an average of 77.5% per year for the next 3 years

Volatile share price over the past 3 months compared to the German market

8ZD Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,582 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

479,582 investors already sharing narratives

View all narratives

Abbisko Cayman Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Abbisko Cayman
Historical stock prices
Current Share Price	HK$1.17
52 Week High	HK$2.10
52 Week Low	HK$0.95
Beta	1.21
1 Month Change	18.78%
3 Month Change	-19.86%
1 Year Change	10.38%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-5.87%

Recent updates

Shareholder Returns

	8ZD	DE Biotechs	DE Market
7D	-6.4%	-0.1%	0.1%
1Y	10.4%	11.4%	-0.5%

Return vs Industry: 8ZD underperformed the German Biotechs industry which returned 13.3% over the past year.

Return vs Market: 8ZD exceeded the German Market which returned 0.3% over the past year.

Price Volatility

Is 8ZD's price volatile compared to industry and market?
8ZD volatility
8ZD Average Weekly Movement	7.9%
Biotechs Industry Average Movement	7.7%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 8ZD's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8ZD's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2016	276	Yao-Chang Xu	www.abbisko.com

Abbisko Cayman Limited, together with its subsidiaries, engages in the research, discovery, and development of pharmaceutical products in Mainland China and the European Union. The company develops Pimicotinib (ABSK021), a small molecule CSF-1R inhibitor, which is in NDA/commercial stage for the treatment of tenosynovial giant cell tumors and Phase Ib/II for the treatment of chronic graft versus host disease; and Irpagratinib (ABSK011), a small-molecule inhibitor of FGFR4, which is in pivotal stage and Phase Ib/II for the treatment of hepatocellular carcinoma. It also engages in the development of ABSK061, which is in Phase Ib/II for the treatment of gastric cancer and achondroplasia; and ABSK043, which is in Phase Ib/II for the treatment of solid tumors and non-small cell lung cancer.

Abbisko Cayman Limited Fundamentals Summary

How do Abbisko Cayman's earnings and revenue compare to its market cap?
8ZD fundamental statistics
Market cap	€844.01m
Earnings (TTM)	€7.15m
Revenue (TTM)	€79.20m

118.1x

P/E Ratio

10.7x

P/S Ratio

Is 8ZD overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8ZD income statement (TTM)
Revenue	CN¥612.12m
Cost of Revenue	CN¥0
Gross Profit	CN¥612.12m
Other Expenses	CN¥556.87m
Earnings	CN¥55.25m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	0.077
Gross Margin	100.00%
Net Profit Margin	9.03%
Debt/Equity Ratio	15.2%

How did 8ZD perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/22 20:41
End of Day Share Price	2026/07/22 00:00
Earnings	2025/12/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbisko Cayman Limited is covered by 20 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ziyu He	China International Capital Corporation Limited
null null	China International Capital Corporation Limited
Jin Zhang	China International Capital Corporation Limited

Abbisko Cayman (8ZD) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Abbisko Cayman Limited Competitors

2invest

Novogenia

2invest

Lepu Biopharma

Price History & Performance

Recent News & Updates

New minor risk - Share price stability

Abbisko Cayman Limited has completed a Follow-on Equity Offering in the amount of HKD 522.522 million.

Abbisko Therapeutics Showcases Six Research Advances Highlighting Pan-KRAS, 4th Generation EGFR, And Synthetic Lethality Approaches

Abbisko Cayman Limited has filed a Follow-on Equity Offering in the amount of HKD 522.522 million.

Abbisko Therapeutics Co., Ltd. Announces U.S. Food and Drug Administration Cleared the Investigational New Drug Application for ABSK061

Abbisko Cayman Limited, Annual General Meeting, May 20, 2026

Recent updates

New minor risk - Share price stability

Abbisko Cayman Limited has completed a Follow-on Equity Offering in the amount of HKD 522.522 million.

Abbisko Therapeutics Showcases Six Research Advances Highlighting Pan-KRAS, 4th Generation EGFR, And Synthetic Lethality Approaches

Abbisko Cayman Limited has filed a Follow-on Equity Offering in the amount of HKD 522.522 million.

Abbisko Therapeutics Co., Ltd. Announces U.S. Food and Drug Administration Cleared the Investigational New Drug Application for ABSK061

Abbisko Cayman Limited, Annual General Meeting, May 20, 2026

Abbisko Cayman Limited to Report Fiscal Year 2025 Results on Mar 02, 2026

Abbisko Therapeutics Announces FDA Acceptance of the Nda for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor

Abbisko Cayman Limited to Report First Half, 2025 Results on Aug 04, 2025

Abbisko Therapeutics Co., Ltd. Completes First Patient Enrollment of Observational Study for the Treatment of Achondroplasia

Abbisko Therapeutics Announces China NMPA Acceptance of New Drug Application for Pimicotinib for the Treatment of TGCT

Abbisko Therapeutics Receives CDE Approval of Breakthrough Therapy Designation for Irpagratinib (ABSK011) in the Treatment of HCC

Abbisko Therapeutics to Present Updated Results from the Phase 2 Study of Irpagratinib in Combination with Atezolizumab for the Treatment of Advanced Hepatocellular Carcinoma at the 2025 ESMO GI Congress

Abbisko Cayman Limited, Annual General Meeting, Jun 18, 2025

Abbisko Cayman Limited Announces Board and Committee Changes

Abbisko Cayman Limited to Report Fiscal Year 2024 Results on Mar 03, 2025

Abbisko Cayman Limited Provides Unaudited Group Earnings Guidance for the Year Ended December 31, 2024

Abbisko Cayman Limited Announces Resignation of Tang Yanmin as Non-Executive Director

Abbisko Therapeutics Co., Ltd. Announces Dosed in Phase II Clinical Study of ABSK043, an Oral PD-L1 Small-Molecule Inhibitor, in Combination with Furmonertinib for NSCLC

New major risk - Share price stability

Abbisko Cayman Limited Announces Pimicotinib Significantly Improved Outcomes for Patients with Tenosynovial Giant Cell Tumor in a Global Phase III Trial

First half 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.32 loss in 1H 2023)

First half 2024 earnings released: EPS: CN¥0.32 (vs CN¥0.32 loss in 1H 2023)

Abbisko Cayman Limited to Report First Half, 2024 Results on Aug 12, 2024

Abbisko Therapeutics Co., Ltd. Presents New Phase II Clinical Data of Its Highly Selective FGFR4 Inhibitor Irpagratinib (ABSK011) in Combination with Atezolizumab for the 2024 Esmo-Gi Congress

Abbisko Cayman Limited Announces Resignation of Tian Huimin as Joint Company Secretary

Abbisko Therapeutics Co., Ltd. Completes All Patient Enrollment for the Global Phase III TGCT Trial of Its CSF-1R Inhibitor - Pimicotinib

Abbisko Cayman Limited (SEHK:2256) commences an Equity Buyback for 70,219,935 shares, representing 10% of its issued share capital, under the authorization approved on June 14, 2023.

Abbisko Cayman Limited to Report Fiscal Year 2023 Results on Mar 12, 2024

Less than half of directors are independent

Less than half of directors are independent

Abbisko Therapeutics Announces U.S. FDA Grants Fast Track Designation for CSF-1R Inhibitor Pimicotinib (ABSK021)

Abbisko Therapeutics Completed the First Patient Dose in the Phase II Advanced Pancreatic Cancer Trial of CSF-1R Inhibitor Pimicotinib (ABSK021) in China

Abbisko Therapeutics Co., Ltd. Obtains the Clinical Trial Approval from NMPA for its Next-Generation Small Molecule CD73 Inhibitor ABSK051

Abbisko Therapeutics Co., Ltd. Presents Two Clinical Updates of Pimicotinib at the 2023 Connective Tissue Oncology Society Annual Meeting

Less than half of directors are independent

Abbisko Cayman Limited to Debut Two Major Clinical Research Results At the 2023 European Society for Medical Oncology

Abbisko Cayman Limited Announces Absk011 Hcc Combo Clinical Trial Approved by Nmpa

Abbisko Cayman Limited to Report First Half, 2023 Results on Aug 15, 2023

Abbisko Cayman Limited Announces Resignation of Dr. XIA Gavin Guoyao as Non-Executive Director

Abbisko Therapeutics Co., Ltd. to Present the Updated Clinical Phase Ib Data of Pimicotinib (ABSK021)

US FDA Grants Breakthrough Therapy Designation for CSF-1R Inhibitor Pimicotinib(ABSK021) of Abbisko Therapeutics

Less than half of directors are independent

Abbisko Therapeutics Co., Ltd. Completed the Dosing of the First Patient in China for Its Small-Molecule PD-L1 Inhibitor ABSK043

Abbisko Cayman Limited Appoints Zhang Zidong as Chief Financial Officer

Less than half of directors are independent

Key Executive recently bought €123k worth of stock

Less than half of directors are independent

Shareholder Returns

Price Volatility

About the Company

Abbisko Cayman Limited Fundamentals Summary

Earnings & Revenue

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources